SUMMARY The 15-year survival of a group of 205 patients who started treatment in the period 1962 through 1966 and who received methyldopa for two-thirds or more of the time has been investigated. At entry these patients had severe hypertension with an average pretreatment pressure of 216/126 mm Hg. Twenty-one percent had retinal hemorrhages, cotton-wool spots, or papilledema. Blood pressure showed a large fall in the first year, followed by a small, progressive, further fall up to the sixth year. After 5 years of treatment the blood pressure averaged 144/90 mm Hg in men and 151/ 91 mm Hg in women. The average daily dose of methyldopa was approximately 1500 mg and changed little over the 15-year period. Survival was analyzed by life tables. Approximately 81% of men and women aged 30 to 49.9 years at entry were still alive 10 years later. In the age group 60 to 69.9 years, 53.8% of men and 63.2% of women were still alive 10 years later. Seventy-nine of the patients died during the follow-up period, 89% from cardiovascular or renal disease. Ischemic heart disease (40%) was the major cause of death, followed by stroke (19%). No patients died from drug toxicity. 
T HE Hammersmith Hospital Hypertension Clinic was set up in 1951 to 1952 shortly after the introduction of the quaternary ammonium ganglion-blocking drugs into therapeutics. Since that time the clinic has maintained complete registers, initially manually and for the last 12 years on a digital computer, which enable all patients in whom antihypertensive treatment was initiated to be identified. Most patients in whom treatment is undertaken are followed up indefinitely, at intervals that depend on their blood pressure control. Patients in whom blood pressure has been good for 3 to 5 years are seen in the clinic only once or twice a year. In the interval between visits the patients are under the care of their family doctor. Those who are not under good control are seen at more frequent intervals.
A number of studies of long-term survival have been made that use the clinic records as a starting point. The great majority of the patients are registered with the Office of Population Censuses and Surveys (OPCS), which ensures that a copy of their death certificate (if they die in the UK) is forwarded to the clinic clerks within a few weeks of death. The present study forms part of a larger investigation of the outcome for pa- tients whose treatment began in the period 1962 through 1966. This period was selected because it marked the beginning of the modern era of antihypertensive therapy, after use of ganglionic-blocking drugs had declined and before /3-blocking drugs came into widespread use. The principal drugs used during this time were thiazide diuretics, methyldopa, and the adrenergic neuron-blocking drugs bethanidine and guanethidine. This report is mainly concerned with the outcome of treatment in those patients in whom methyldopa was the principal therapeutic agent used throughout most of the treatment period.
Methods
All the patients whose names were recorded in the clinic log books from 1962 through 1966 were included in this study. Six-hundred-and-sixty patients were identified and the records of 646 were recovered from the hospital files. Forty-nine were not considered further, either because blood pressure subsided without antihypertensive therapy or the patients were resident abroad at the time they were seen and only short-term follow-up was possible. The remaining 597 patients were registered with the OPCS. Eighty patients who had been lost to follow-up from the clinic could not be traced by the OPCS, but other enquiries revealed that 18 were dead and 11 were still living at the end of the selected study period. This left 51 patients (8.5%) who could not be traced. 
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The study follow-up period terminated in July 1981 when the last patients to have been recruited would have completed 15 years' treatment if they were still alive. The hypertension clinic case records were very carefully scrutinized and information was extracted from the initial referral up to July 1981. The information obtained included age, sex, race, untreated blood pressure, smoking habits, family history of hypertension, retinal appearances, weight, and biochemical data at presentation. The data were not complete, for example, 31% of patients were already on treatment at presentation so that pretreatment blood pressures were not available.
Follow-up information was also extracted and included all blood pressure readings with their dates, full details of all antihypertensive therapy, and all measurements of potassium, urea, creatinine, cholesterol, uric acid and hemoglobin levels. Details of complications such as nonfatal myocardial infarction and stroke also were recorded. The patients were defined as having been treated with methyldopa if they had received this drug for at least two-thirds of their total follow-up period; 205 patients fulfilled this definition.
Statistical Methods
Survival was analyzed with standard life-table techniques. When groups were compared for characteristics other than survival the unpaired /-test, analysis of variance, or chi-square test was used as appropriate. To determine the effect of different variables on survival, the Cox regression model was used.
Results
The average age of the patients when treatment was started was 49.9 ± 11.7 years and the average untreated blood pressure was 216/126 mm Hg. Data for men and women are given separately in Table 1 . Fortythree patients who had papilledema or retinal cottonwool spots fell within the definition of accelerated hypertension. Thus, by current standards, the patients included in the study were severely hypertensive. Nearly two-thirds of the men smoked tobacco and more than one-third of the women were smokers. The most commonly used drugs after 1 year of treatment were thiazide diuretics (60%-70%), followed by methyldopa (50%-60%), bethanidine (20%), and guanethidine (6%). Very few patients were ever given high-ceiling diuretics or potassium-conserving diuretics. Later in the follow-up period an increasing number of patients were treated with propranolol. The average dose of methyldopa increased from 1230 mg daily to 1575 mg daily in men over the period of follow-up. Average doses in women were approximately 100 mg/day less ( Figure 1 ). Blood pressure control showed a progressive improvement during the first 5-year period of follow-up and a small further fall between 5 and 10 years ( Figure  2A, B) . The blood pressure at the fifth year of followup averaged 144/90 mm Hg in men and 151/91 mm Hg in women treated with methyldopa.
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Length of Survival
Survival was analyzed by means of life tables. Data for three age ranges in men and women are given in Table 2 . Patients aged 30 to 59.9 years have been combined in Figure 3 . There were too few patients under age 30 or over 69.9 years at the start of treatment to make analyzing them as separate groups worthwhile. The numbers in each of the three age groups analyzed in Table 2 are not large and there are some anomalies, for example, women aged 50 to 59.9 years at entry had a better survival than those 10 years younger. The general pattern, however, is clear. Approximately 81% of men and women aged 30 to 49.9 years at entry were still alive 10 years later. In the age group 60 to 69.9 years, 53.8% of men and 63.2% of women were still alive after 10 years of treatment, when the mean age of this group had reached 75 years. They were then at an age at which there is substantial mortality among the general population of England and Wales. The mortality of the treated group was somewhat higher than that of the general population, particularly at the younger ages; for example, the 10-year mortality of a 42-year-old man or woman in the population at large is only 2% to 3%, compared with 19% among the treated patients. The survival of the 60-to 69.9-year-old patients, however, was only slightly worse than that of the general population of the same age and sex.
Causes of Death
The underlying causes of death given on the death certificates are listed in Table 3 . Eighty-nine percent of the deaths were due to cardiovascular or renal disease; only 10% were from cancer. Ischemic heart disease was the most frequent cause of death (40%), followed by stroke (19%). There were only two patients whose death was certified as being due to renal disease. None died from drug toxicity.
The patients who died had higher pressures at presentation and were more likely to be male and to smoke cigarettes than were those who survived ( Table 4 ). The concentration of urea in the plasma during treatment was, on average, higher in those who died than in those who lived. There was no association between serum potassium levels during treatment and outcome. The serum cholesterol was not a useful predictor of survival but it did correlate with the cause of death: Patients who died of ischemic heart disease had higher levels of cholesterol; those who died of cancer had lower-thanaverage levels. Body weight was not a useful predictor of survival.
Smokers had a higher mortality than nonsmokers; the excess mortality was caused by ischemic heart disease, stroke, and cancer. Discussion Antihypertensive therapy may be used continuously for a substantial fraction of a patient's life span. Although clinical trials provide the only conclusive evidence of the efficacy of treatment, they are usually of only 3-to 5-years' duration. Both the efficacy and the safety of drugs may differ over long periods of treatment from the results found in medium-term clinical trials. Clinic records can provide a means of filling this gap provided certain conditions are met. These conditions include adequate documentation of the patient at the initiation of treatment, follow-up information on 
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(11.4) (42.9) (22.9) (8.6) (2.9) (5.7) (2.9) (2.9) blood pressure control, and information about the cause of death -with only a small proportion of patients untraced. All these conditions were met in this study, which records treatment over a period of at least 15 years in each patient who survived.
Our data showed a satisfactory survival of the patients when compared with untreated series, such as data reported by Smirk and his colleagues from New Zealand 1 and by Bulpitt. 2 Without a randomly allocated control group it is impossible to prove that these patients' long survival was due to specific antihypertensive therapy, although this explanation seems likely. Another approach is to compare the patients' survival with the general population of the same age and sex. 1 The results of doing so are, at first sight, surprising.
For the oldest age group the survival of the treated patients was only slightly worse than that of the general population of the same age. The expected 10-year survival of a man aged 63 years is 57%, and the observed 10-year survival of the treated male hypertensive patients aged 60 to 69 was 54%. The corresponding figures for women of the same ages were 74% in the general population and 63% in the treated patients. These are relatively small differences. The pattern in the younger patients was less favorable: among the patients aged 30 to 49 years at the outset the 10-year survival was 81% in both women and men. The expected 10-year survival of men and women of this age is 96% to 98%. Thus, although the survival was relatively good, mortality was substantially greater than in the general population.
The blood pressure control achieved after 5 years of treatment was fairly satisfactory even by contemporary standards -an average of 147/92 mm Hg. This level of diastolic blood pressure was associated with very little increase in risk among patients in the Framingham study. 4 The reason for the slow improvement in control for the first 5 years is not entirely clear. Progressive small changes in drug therapy may have played a part, although the upward adjustment of methyldopa dose over this period was, on average, very small. Reversal of cardiovascular hypertrophy may also have been important. Whatever the reason it is gratifying that blood pressure control tended to improve, even though in untreated patients with high blood pressure levels an upward trend is common.
Deaths were predominantly from cardiovascular and renal causes. Thus, the mortality pattern still reflected that expected in hypertensive patients rather than in the general population. There were no deaths from liver disease, carcinoma of the biliary tree, hemolytic anemia, 5 6 or any other cause that might have raised suspicion of drug toxicity.
These patients with severe hypertension treated predominantly with methyldopa had a remarkably long survival but, especially at the younger ages, they still had a higher mortality than that of the general population of the same age and sex. This rinding was not particular to methyldopa, because patients treated predominantly with bethanidine and guanethidine showed the same pattern. One possible explanation for the similarity of the older patients' survival to that of the general population might be that hypertension, treated or untreated, has only a minor effect on survival in older patients; however, this is not in accord with epidemiologic evidence. 7 Another possible explanation may be that treatment is particularly effective in the older patients.
The less favorable effect on mortality in younger patients is also difficult to explain. Secondary hypertension is somewhat more common in younger patients, and excess deaths from chronic renal disease (which itself caused the hypertension), could provide an explanation. Both deaths from chronic renal disease occurred in patients who were under 30 years old at entry but there were too few renal deaths to invoke this as the whole explanation. Another possibility is that atheromatous vascular disease caused by hypertension could not be reversed by blood pressure control. If, however, this hypothesis was true, the same, or greater, effect should be seen in the elderly and it was not. At present no entirely satisfactory explanation is possible but the data do draw attention to the problems of moderately severe hypertension in younger patients. While much progress has been achieved, a normal life expectancy has not yet been attained.
